Skip to Main Content
Newsroom
BD & Partnering
Get in Touch
LinkedIn
X Mobile
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
BD & Partnering
Get in Touch
LinkedIn
X Mobile
ASGCT POAG Presentation
May 9, 2024
By
+
-
Editas Newsroom
Sep
2
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Aug
28
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Aug
27
Editas Medicine to Participate in Upcoming Investor Conferences